1028481-80-2

Upstream product

• 1028481-52-8 (2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-((E)-4-((2R,6S)-6-(((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxy-dihydro-2H-pyran-3(4H)-one 
• 365404-48-4 5-benzyloxy-3-(tert-butyl-dimethyl-silanyloxy)-pentanoic acid ethyl ester 
• 1028481-67-5 ethyl (R)-3-(tert-butyldimethylsilyloxy)-4-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)butanoate 
• 1028481-45-9 ethyl (R)-3-(tert-butyldimethylsilyloxy)-5-oxopentanoate 
• 1028481-50-6 (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enal 
• 1028481-78-8 S-ethyl (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxybenzyloxy)butyl)-2-(tert-butyldimethylsilyloxy)butyl-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enethioate 
• 1028481-76-6 S-ethyl (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxybenzyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enethioate 
• 854931-23-0 (E)-4-{(S)-6-[(2R,3R)-3-Benzyloxymethoxy-2-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-4-methyl-pent-2-enethioic acid S-ethyl ester 
• 1028481-48-2 (S)-1-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-4-((trimethylsilyl)methyl)pent-4-en-2-ol 
• 1028481-73-3 ethyl (R)-4-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-(trimethylsilyloxy)butanoate 
• 1028481-71-1 ethyl (R)-4-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-hydroxy-butanoate 
• 1028481-69-7 ethyl (R)-4-((2R,6S)-6-((S)-4-(hydroxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-hydroxy-butanoate 

Downstream Products

• 1028481-82-4 (R)-4-((2S,6R)-6-(((2S,6R)-6-((E)-3-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-3-(4-methoxybenzyloxy)butanal 
• 1190429-50-5 C₄₈H₆₆O₁₁ 
• 1190429-51-6 C₅₆H₈₀O₁₂ 
• 1028481-54-0 (R)-4-((2S,6R)-6-(((2S,6R)-6-((E)-3-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-3-(4-methoxybenzyloxy)butanoic acid 
• 1028481-56-2 17-{(1S)-1-[(phenylmethoxy)methoxy]ethyl}(11S,17S,1R,3R,7R,21R,23R)-11-methoxy-10,10-dimethyl-5,25-dimethylene-18,27,28,29-tetraoxa-21-(4-methoxybenzyloxy)tetracyclo[21.3.1.1^3,7.1^17,15]nonacosa-8-ene-12,19-dione 
• 1028481-58-4 methyl 2-(11-methoxy-10,10-dimethyl-5,25-dimethylene-12,19-dioxo-17-{[(phenylmethoxy)methoxy]ethyl}-21-(4-methoxybenzyloxy)-18,27,28,29-tetraoxatetracyclo[21.3.1.1^3,7.1^11,15]nonacosa-8-en-13-ylidene) acetate 
• 1028481-90-4 C₅₁H₆₈O₁₄ 
• 1028481-60-8 C₄₁H₅₄O₁₂ 
• 1190587-51-9 C₅₆H₈₀O₁₂ 

Relevant academic research and scientific papers

BRYOSTATIN ANALOGS AND USE THEREOF AS ANTIVIRAL AGENTS

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including the treatment or prevention of viral infection. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in a low number of steps and with a high degree of substitution and specificity.

MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.

Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: Bryostatin look-alikes that mimic phorbol ester function

Highly potent bryostatin analogues which contain the complete bryostatin core structure have been synthesized using a pyran annulation approach as a key strategic element. The A ring pyran was assembled using a pyran annulation reaction between a C1-C8 hydroxy allylsilane and an aldehyde comprising C9-C13. This pyran was transformed to a new hydroxy allylsilane and then coupled with a preformed C ring aldehyde subunit in a second pyran annulation, with concomitant formation of the B ring. This tricyclic intermediate was elaborated to bryostatin analogues which displayed nanomolar to subnanomolar affinity for PKC, but displayed properties indistinguishable from a phorbol ester in a proliferation/attachment assay. Copyright